Tiverton Asset Management LLC reduced its position in Mednax (NYSE:MD) by 40.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,316 shares of the company’s stock after selling 148,715 shares during the quarter. Tiverton Asset Management LLC owned about 0.24% of Mednax worth $12,367,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC bought a new position in shares of Mednax in the fourth quarter valued at approximately $3,167,000. FDx Advisors Inc. raised its stake in Mednax by 10.5% in the fourth quarter. FDx Advisors Inc. now owns 15,304 shares of the company’s stock valued at $818,000 after purchasing an additional 1,450 shares in the last quarter. American International Group Inc. raised its stake in Mednax by 1.2% in the fourth quarter. American International Group Inc. now owns 197,889 shares of the company’s stock valued at $10,575,000 after purchasing an additional 2,306 shares in the last quarter. Paloma Partners Management Co raised its stake in Mednax by 239.9% in the fourth quarter. Paloma Partners Management Co now owns 128,825 shares of the company’s stock valued at $6,884,000 after purchasing an additional 90,925 shares in the last quarter. Finally, GHP Investment Advisors Inc. raised its stake in Mednax by 13.8% in the fourth quarter. GHP Investment Advisors Inc. now owns 7,735 shares of the company’s stock valued at $413,000 after purchasing an additional 940 shares in the last quarter. Institutional investors own 99.37% of the company’s stock.
Mednax opened at $46.53 on Tuesday, Marketbeat.com reports. The company has a market cap of $4.36 billion, a price-to-earnings ratio of 14.77, a price-to-earnings-growth ratio of 1.17 and a beta of 0.26. Mednax has a one year low of $45.96 and a one year high of $46.48. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.63.
Mednax (NYSE:MD) last posted its quarterly earnings results on Monday, April 30th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The firm had revenue of $901.90 million for the quarter, compared to the consensus estimate of $903.75 million. Mednax had a net margin of 9.34% and a return on equity of 10.13%. The business’s revenue was up 7.9% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. analysts anticipate that Mednax will post 3.95 EPS for the current year.
In related news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total value of $175,050.00. Following the transaction, the insider now directly owns 39,716 shares of the company’s stock, valued at $2,317,428.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.70% of the stock is owned by insiders.
A number of brokerages recently weighed in on MD. JPMorgan Chase raised their target price on shares of Mednax from $46.00 to $55.00 and gave the company a “neutral” rating in a research note on Monday, February 12th. Zacks Investment Research downgraded shares of Mednax from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. BMO Capital Markets raised their target price on shares of Mednax from $46.00 to $58.00 and gave the company a “market perform” rating in a research note on Monday, February 12th. Mizuho reaffirmed a “neutral” rating and issued a $53.00 target price (up from $49.00) on shares of Mednax in a research note on Friday, February 9th. Finally, Jefferies Group set a $50.00 target price on shares of Mednax and gave the company a “hold” rating in a research note on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $55.92.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax (NYSE:MD).
Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.